首页 / 院系成果 / 成果详情页

Tc-99m-3PRGD(2) SPECT to monitor early response to neoadjuvant chemotherapy in stage II and III breast cancer 期刊论文

编号：

3869a092-a031-42c1-a8fa-deac38bec852
作者：

Ji, Bin(纪滨)#^[1]Chen, Bin(陈滨)#^[1]Wang, Ting(王婷)^[1]Song, Yan(宋研)^[2]Chen, Minglong(陈明龙)^[1]Ji, Tiefeng(纪铁凤)^[1]Wang, Xueju(王学菊)^[3]Gao, Shi(高识)*^[1]Ma, Qingjie(马庆杰)*^[1]
语种：

英文
期刊：

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING ISSN：1619-7070 2015 年 42 卷 9 期 (1362 - 1370) ; AUG
收录：
关键词：

Tc-99m-3PRGD(2) SPECT Breast cancer Neoadjuvant chemotherapy Therapy monitoring Residual cancer burden
摘要：

Purpose Monitoring of response to neoadjuvant chemotherapy (NCT) is important for optimal management of patients with breast cancer. Tc-99m-3PRGD(2) SPECT is a newly developed imaging modality for evaluating tumor vascular status. In this study, we investigated the application of Tc-99m-3PRGD(2) SPECT in evaluating therapy response to NCT in patients with stage II or III breast cancer.
Methods Thirty-three patients were scheduled to undergo Tc-99m-3PRGD(2) SPECT at baseline, after the first and second cycle of NCT. Four patients had extremely low Tc-99m-3PRGD(2) uptake at baseline, and were not included in the subsequent studies. Changes in tumor to nontumor (T/N) ratio were compared with pathological tumor responses classified using the residual cancer burden system. Receiver operator characteristic analysis was used to compare the power to identify responders between the end of the first and the end of the second cycle of NCT. The impact of breast cancer subtype on Tc-99m-3PRGD(2) uptake was evaluated. The correlation between Tc-99m-3PRGD(2) uptake and pathological tumor response was also evaluated in each breast cancer subtype.
Results Surgery was performed after four cycles of NCT and pathological analysis revealed 18 responders and 15 nonresponders. In patients with clearly visible Tc-99m-3PRGD(2) uptake at baseline, the sensitivity, specificity, and negative predictive value of Tc-99m-3PRGD(2) SPECT were 86.7 %, 85.7 % and 86.7 % after the first cycle of NCT, and 92.9 %, 93.3 % and 93.3 % after the second cycle, respectively. Among these patients, the HER-2-positive group demonstrated both higher T/N ratios and a greater change in T/N ratio than patients with other breast cancer subtypes (P < 0.05). A strong correlation was found between changes in T/N ratio and pathological tumor response in the HER-2-positive group (P < 0.03).
Conclusion Tc-99m-3PRGD(2) SPECT seems to be useful for determining the pathological tumor response in patients with stage II or III breast cancer undergoing NCT, especially those with the HER-2-positive subtype.
推荐引用方式
GB/T 7714：

Ji Bin,Chen Bin,Wang Ting, et al. Tc-99m-3PRGD(2) SPECT to monitor early response to neoadjuvant chemotherapy in stage II and III breast cancer [J].EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING,2015,42(9):1362-1370.
APA：

Ji Bin,Chen Bin,Wang Ting,Song Yan,&Ma Qingjie.(2015).Tc-99m-3PRGD(2) SPECT to monitor early response to neoadjuvant chemotherapy in stage II and III breast cancer .EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING,42(9):1362-1370.
MLA：

Ji Bin, et al. "Tc-99m-3PRGD(2) SPECT to monitor early response to neoadjuvant chemotherapy in stage II and III breast cancer" .EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 42,9(2015):1362-1370.
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：37  下载次数：0

分享到：

浏览次数：37

下载次数：0

打印次数：0